U.S. Oncology In-vivo CRO Market (2024 - 2030) Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumors, Others), And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Indication
                        1.2.2. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                            1.4.5.1. Data for primary interviews in Italy
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Approach 1: Commodity flow approach
                        1.7.3. Volume price analysis (Model 2)
                        1.7.4. Approach 2: Volume price analysis
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Indication
                    2.3. Competitive Insights
Chapter 3. U.S. Oncology In-vivo CRO Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                    3.3. Market Driver Analysis
                    3.4. Market Restraint Analysis
                    3.5. Industry Analysis - Porter’s Five Forces
                        3.5.1. Supplier power
                        3.5.2. Buyer power
                        3.5.3. Substitution threat
                        3.5.4. Threat of new entrant
                        3.5.5. Competitive rivalry
                    3.6. PESTEL Analysis
                        3.6.1. Political landscape
                        3.6.2. Technological landscape
                        3.6.3. Economic Landscape
Chapter 4. U.S. Oncology In-vivo CRO Market Indication Estimates & Trend Analysis
                    4.1. U.S. Oncology In-vivo CRO Indication Model Dashboard
                    4.2. U.S. Oncology In-vivo CRO Market Indication Movement Analysis
                    4.3. Blood cancer
                        4.3.1. Blood cancer market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.3.1.1. Syngeneic model-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.3.1.2. PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.3.1.3. Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
                    4.4. Solid tumors
                        4.4.1. Solid tumors market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.4.1.1. Syngeneic model-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.4.1.2. PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.4.1.3. Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
                    4.5. Others
                        4.5.1. Other market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.5.1.1. Syngeneic model based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.5.1.2. PDX-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
                            4.5.1.3. Xenograft-based solid tumor market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. Competitive Landscape
                    5.1. Recent Developments & Impact Analysis, By Key Market Participants
                    5.2. Company/Competition Categorization
                        5.2.1. Vendor Landscape
                        5.2.2. List of key distributors and channel partners
                        5.2.3. Key customers
                        5.2.4. Key company market share analysis, 2023
                        5.2.5. The Jackson Laboratory
                            5.2.5.1. Company overview
                            5.2.5.2. Financial performance
                            5.2.5.3. Product benchmarking
                            5.2.5.4. Strategic initiatives
                        5.2.6. Charles River Laboratory
                            5.2.6.1. Company overview
                            5.2.6.2. Financial performance
                            5.2.6.3. Product benchmarking
                            5.2.6.4. Strategic initiatives
                        5.2.7. Thermo Fisher Scientific Inc.
                            5.2.7.1. Company overview
                            5.2.7.2. Financial performance
                            5.2.7.3. Product benchmarking
                            5.2.7.4. Strategic initiatives
                        5.2.8. LabCorp
                            5.2.8.1. Company Overview
                            5.2.8.2. Financial performance
                            5.2.8.3. Product benchmarking
                            5.2.8.4. Strategic initiatives
                        5.2.9. Taconic Biosciences
                            5.2.9.1. Company Overview
                            5.2.9.2. Financial performance
                            5.2.9.3. Product benchmarking
                            5.2.9.4. Strategic initiatives
                        5.2.10. Crown Bioscience
                            5.2.10.1. Company Overview
                            5.2.10.2. Financial performance
                            5.2.10.3. Product benchmarking
                            5.2.10.4. Strategic initiatives
                        5.2.11. Sierra Oncology, Inc.
                            5.2.11.1. Company Overview
                            5.2.11.2. Financial performance
                            5.2.11.3. Product benchmarking
                            5.2.11.4. Strategic initiatives
                        5.2.12. Coherus BioSciences, Inc
                            5.2.12.1. Company Overview
                            5.2.12.2. Financial performance
                            5.2.12.3. Product benchmarking
                            5.2.12.4. Strategic initiatives
                        5.2.13. Courante Oncology
                            5.2.13.1. Company Overview
                            5.2.13.2. Financial performance
                            5.2.13.3. Product benchmarking
                            5.2.13.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. Blood Pressure Monitoring, By Indication, 2018 - 2030 (USD Billion)

List of Figures

Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Oncology In-vivo CRO Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 U.S. Oncology In-vivo CRO Market: Indication outlook and key takeaways
Fig. 15 U.S. Oncology In-vivo CRO Market: Indication movement analysis & market share 2023 & 2030
Fig. 16 Blood cancer market, 2018 - 2030 (USD Million)
Fig. 17 Syngeneic model-based blood cancer market, 2018 - 2030 (USD Million)
Fig. 18 PDX model-based blood cancer market, 2018 - 2030 (USD Million)
Fig. 19 Xenograft-based blood cancer market, 2018 - 2030 (USD Million)
Fig. 20 Solid tumor market, 2018 - 2030 (USD Million)
Fig. 21 Syngeneic model-based solid tumor market, 2018 - 2030 (USD Million)
Fig. 22 PDX model-based solid tumor market, 2018 - 2030 (USD Million)
Fig. 23 Xenograft-based solid tumor market, 2018 - 2030 (USD Million)
Fig. 24 Other cancers market, 2018 - 2030 (USD Million)
Fig. 25 Syngeneic model-based other cancers market, 2018 - 2030 (USD Million)
Fig. 26 PDX model-based other cancers market, 2018 - 2030 (USD Million)
Fig. 27 Xenograft-based other cancers market, 2018 - 2030 (USD Million)